Current stock page

Stock Analysis

Sanofi (SNY) Stock Analysis

Sanofi (SNY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

SNY Stock Analysis Summary

Sanofi (SNY) currently has an AIQ Score of 68/100, indicating a bullish setup. Risk is the strongest factor at 85/100. Quality is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

SNY at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$48.37
AIQ Score68/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$115.76B
P/E Ratio (TTM)25.1
Forward P/E—
EPS (Q3 FY2026)$1.26
Revenue (Q3 FY2026)$15.23B
Dividend Yield (TTM)4.70%
Beta0.29
Volume1.68M
52-week range$39.07-$52.68
RSI 1476.2
50-Day SMA$42.68
200-Day SMA$44.36
Analyst Price Target$57.00
Next EarningsFeb 4, 2027
As of Nov 13, 2026 · Market close

SNYSanofi

Healthcare / Drug Manufacturers - General

Leader

Strong Relative Position

BullishEdge 8/10
$48.37−$0.09 (−0.19%)

Latest quote

  • Momentum
    64
  • Value
    77
  • Quality
    57
  • Risk resilience
    85
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

SNY Stock Analysis Summary

Sanofi (SNY) currently has an AIQ Score of 68/100, indicating a bullish setup. Risk resilience is the strongest factor at 85/100. Quality is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, SNY has AIQ Score of 68/100 with Risk resilience base of 85/100 and fading Quality at 57/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Risk resilience (85/100) leads while Quality (57/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.19% stock move · SNY classified in Drug Manufacturers - General.

Current Evidence

BullishSNY is in a bullish AIQ regime; Risk resilience is the strongest visible factor at 85/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is SNY Bullish or Bearish Right Now?

SNY currently has a bullish overall setup. Risk Resilience is the strongest factor at 85/100, while Quality is weakest at 57/100. The current evidence suggests a constructive setup.

Bull Case
  • - Risk Resilience is supportive at 85/100.
  • - Price is +13.33% above its 50-day SMA.
  • - Analyst target implies +17.84% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (35 vs 8).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

SNY's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 3 neutral, and 8 sell votes. SNY's 14-day RSI is 76.2, which places the stock in an overbought momentum range. SNY's beta is 0.29, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in SNY?

The largest recent change in SNY is Momentum moving up by 6.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+6.0
Quality
+2.0
Risk
+0.0

What Would Change the SNY Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

SNY Decision Framework

Public evidence layers, setup checks, and risk context for Sanofi.

Sanofi (SNY) Stock Analysis

Sanofi has an AIQ Score of 68/100 in a Bullish regime. Risk is strongest at 85/100. Beta is 0.29, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSNY is in a Bullish AIQ regime with score 68/100.
Signal ConflictThe primary conflict is that risk leads at 85/100 while quality lags at 57/100.
Factor EvidenceMomentum 64/100 · Value 77/100 · Quality 57/100 · Risk 85/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Risk is the strongest factor at 85/100.

TimingWait

Momentum is 64/100 and RSI (14) is 76.2.

Regime fitPass

SNY is in a Bullish regime at 68/100.

Risk controlPass

Risk factor is 85/100 with beta 0.29 and annual volatility 24.14%.

ConflictWait

Current conflict: risk leads at 85/100 while quality lags at 57/100.

AIQ Score
68/100
Price
$48.37
Beta
0.29
RSI (14)
76.2

SNY Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

SNY Fundamentals

SNY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$15.23B
Net income
$3.02B
Free cash flow
$3.24B
View full SNY fundamental analysis

SNY Technical Analysis

SNY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
76.2
Price vs SMA-50
+13.33%
View full SNY technical analysis

SNY Stock Catalysts

Track SNY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 4, 2027
Analyst target
$57.00
News items
3
View SNY earnings and stock catalysts

SNY Dividend Analysis

SNY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
17.68%
Annual dividend
$8.55
Payout ratio
137.48%
View SNY dividend history and analysis

SNY Financial Data

SNY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$15.23B
EPS
$1.26
Periods
8
View SNY financials

SNY Risk Analysis

SNY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.29
Risk score
85/100
1Y volatility
24.14%
View SNY risk analysis

SNY Stock News

SNY stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Nov 15, 2026
Sentiment
—
Read SNY stock news

SNY vs Drug Manufacturers - General Peers

Current peer cohort: SNY · NVS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
SNY
Current stock
68/10077/10064/10085/100-0.3724.14%Current
NVS
Novartis AG
61/10049/10064/10076/1000.7227.23%SNY vs NVS
Pairwise Compare links: NVSSNY vs NVSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a SNY stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for SNY: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
25.1
As of Nov 13, 2026
Revenue growth
15.66%
Gross margin
73.44%
Current debt / equity
0.27
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$15.23B
Quarter net income
$3.02B
Quarter free cash flow
$3.24B

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
76.2
MACD
1.89

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
85/100
Beta
0.29
Annual volatility
24.14%
Max drawdown
-25.26%

SNY Stock FAQ

What is SNY stock price today?

Sanofi's current stock price is $48.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is SNY bullish or bearish right now?

SNY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is SNY's market cap?

SNY's market cap is $115.76B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is SNY's current P/E ratio?

SNY's current P/E ratio is 25.1 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is SNY's RSI?

SNY's 14-day RSI is 76.2 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is SNY above its 50-day and 200-day moving averages?

SNY is 13.33% from its 50-day SMA and 9.03% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is SNY's next earnings date?

SNY's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does SNY pay a dividend?

SNY's dividend yield is 4.70% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.